TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Follow up After Self-poisoning by General Practitioner- a Randomised Clinical Trial
Brief Summary: The study hypothesis is that follow up from general practitioner after hospitalization for self poisoning will decrease suicidal behaviour.


Options:
A: Arm Label: Short-term MBT; Type: EXPERIMENTAL; Interventions: Other: Short-term MBT | Arm Label: Long-term MBT; Type: ACTIVE_COMPARATOR; Interventions: Other: Long-term MBT | Intervention Type: OTHER; Name: Short-term MBT; Assigned to Arm(s): Short-term MBT | Intervention Type: OTHER; Name: Long-term MBT; Assigned to Arm(s): Long-term MBT
B: Arm Label: Follow up; Type: EXPERIMENTAL; Interventions: Behavioral: Follow up | Arm Label: Usual Treatment; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Follow up; Assigned to Arm(s): Follow up
C: Arm Label: App-Condition; Type: EXPERIMENTAL; Interventions: Device: Monsenso DBT-app and IT monitoring program | Arm Label: Paperdiary-condition; Type: ACTIVE_COMPARATOR; Interventions: Other: Paper diary sheet | Intervention Type: OTHER; Name: Paper diary sheet; Assigned to Arm(s): Paperdiary-condition | Intervention Type: DEVICE; Name: Monsenso DBT-app and IT monitoring program; Assigned to Arm(s): App-Condition
D: Arm Label: Case management; Type: EXPERIMENTAL; Interventions: Behavioral: Case management | Arm Label: Enhanced usual care; Type: ACTIVE_COMPARATOR; Interventions: Other: Enhanced usual care | Intervention Type: BEHAVIORAL; Name: Case management; Assigned to Arm(s): Case management | Intervention Type: OTHER; Name: Enhanced usual care; Assigned to Arm(s): Enhanced usual care

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Follow up After Self-poisoning by General Practitioner- a Randomised Clinical Trial
Brief Summary: The study hypothesis is that follow up from general practitioner after hospitalization for self poisoning will decrease suicidal behaviour.


Options:
A: Arm Label: Treatment with a probiotic; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Treatment with a probiotic | Arm Label: Treatment with placebo powder; Type: PLACEBO_COMPARATOR; Interventions: Other: Treatment with placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Treatment with a probiotic; Assigned to Arm(s): Treatment with a probiotic | Intervention Type: OTHER; Name: Treatment with placebo; Assigned to Arm(s): Treatment with placebo powder
B: Arm Label: Combined psychotherapy; Type: EXPERIMENTAL; Interventions: Behavioral: Combined psychotherapy | Arm Label: Outpatient individual psychotherapy; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Outpatient individual psychotherapy | Intervention Type: BEHAVIORAL; Name: Combined psychotherapy; Assigned to Arm(s): Combined psychotherapy | Intervention Type: BEHAVIORAL; Name: Outpatient individual psychotherapy; Assigned to Arm(s): Outpatient individual psychotherapy
C: Arm Label: SIC + NET; Type: EXPERIMENTAL; Interventions: Behavioral: Narrative Exposure Therapy, Behavioral: Standard Inpatient Care, Other: Waiting List | Arm Label: SIC + DBT; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Dialectical Behavior Therapy, Behavioral: Standard Inpatient Care, Other: Waiting List | Intervention Type: BEHAVIORAL; Name: Narrative Exposure Therapy; Assigned to Arm(s): SIC + NET | Intervention Type: BEHAVIORAL; Name: Dialectical Behavior Therapy; Assigned to Arm(s): SIC + DBT | Intervention Type: BEHAVIORAL; Name: Standard Inpatient Care; Assigned to Arm(s): SIC + DBT, SIC + NET | Intervention Type: OTHER; Name: Waiting List; Assigned to Arm(s): SIC + DBT, SIC + NET
D: Arm Label: Follow up; Type: EXPERIMENTAL; Interventions: Behavioral: Follow up | Arm Label: Usual Treatment; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Follow up; Assigned to Arm(s): Follow up

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 12-week Study to Evaluate the 24 Hour Pulmonary Function of Fluticasone Furoate (FF)/Vilanterol Inhalation Powder (FF/VI Inhalation Powder) Once Daily Compared With Salmeterol/Fluticasone Propionate (FP) Inhalation Powder Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Brief Summary: The purpose of this study is to evaluate the 24-hour spirometry effect (FEV1) of Fluticasone Furoate/Vilanterol 100/25mcg once daily compared with Salmeterol/Fluticasone Propionate 50/500mcg twice daily over a 12-week treatmen period in subjects with COPD.


Options:
A: Arm Label: QVA149 + placebo to tiotropium; Type: EXPERIMENTAL; Interventions: Drug: QVA149, Drug: Placebo to tiotropium, Drug: Salbutamol/albuterol | Arm Label: Tiotropium + placebo to QVA149; Type: ACTIVE_COMPARATOR; Interventions: Drug: Tiotropium, Drug: Placebo to QVA149, Drug: Salbutamol/albuterol | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo to QVA149, Drug: Placebo to tiotropium, Drug: Salbutamol/albuterol | Intervention Type: DRUG; Name: QVA149; Assigned to Arm(s): QVA149 + placebo to tiotropium | Intervention Type: DRUG; Name: Tiotropium; Assigned to Arm(s): Tiotropium + placebo to QVA149 | Intervention Type: DRUG; Name: Placebo to QVA149; Assigned to Arm(s): Placebo, Tiotropium + placebo to QVA149 | Intervention Type: DRUG; Name: Placebo to tiotropium; Assigned to Arm(s): Placebo, QVA149 + placebo to tiotropium | Intervention Type: DRUG; Name: Salbutamol/albuterol; Assigned to Arm(s): Placebo, QVA149 + placebo to tiotropium, Tiotropium + placebo to QVA149
B: Arm Label: QVA149; Type: EXPERIMENTAL; Interventions: Drug: QVA149 | Arm Label: Long acting B2 agonist (LABA) and inhaled corticosteroid (ICS); Type: ACTIVE_COMPARATOR; Interventions: Drug: Long acting B2 agonist (LABA) and inhaled corticosteroid (ICS) | Intervention Type: DRUG; Name: QVA149; Assigned to Arm(s): QVA149 | Intervention Type: DRUG; Name: Long acting B2 agonist (LABA) and inhaled corticosteroid (ICS); Assigned to Arm(s): Long acting B2 agonist (LABA) and inhaled corticosteroid (ICS)
C: Arm Label: Umeclidinium 62.5 mcg; Type: EXPERIMENTAL; Interventions: Drug: Umeclidinium | Arm Label: Glycopyrronium 44 mcg; Type: EXPERIMENTAL; Interventions: Drug: Glycopyrronium | Intervention Type: DRUG; Name: Umeclidinium; Assigned to Arm(s): Umeclidinium 62.5 mcg | Intervention Type: DRUG; Name: Glycopyrronium; Assigned to Arm(s): Glycopyrronium 44 mcg
D: Arm Label: Fluticasone Furoate/Vilanterol; Type: EXPERIMENTAL; Interventions: Drug: Fluticasone Furoate 100mcg/Vilanterol 25mcg | Arm Label: Fluticasone Propionate/Salmeterol; Type: ACTIVE_COMPARATOR; Interventions: Drug: Fluticaosne Propionate 500mcg/Salmeterol 50mcg | Intervention Type: DRUG; Name: Fluticasone Furoate 100mcg/Vilanterol 25mcg; Assigned to Arm(s): Fluticasone Furoate/Vilanterol | Intervention Type: DRUG; Name: Fluticaosne Propionate 500mcg/Salmeterol 50mcg; Assigned to Arm(s): Fluticasone Propionate/Salmeterol

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter, Open-label, Randomized Phase III Study to Evaluate the Efficacy and Safety of Erlotinib (Tarceva®) Versus Gemcitabine/Cisplatin as the First-line Treatment for Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC) Patients With Mutations in the Tyrosine Kinase Domain of Epidermal Growth Factor Receptor (EGFR) in Their Tumors
Brief Summary: This open-label, randomized, parallel arm study assessed the efficacy and safety of Tarceva (erlotinib) versus gemcitabine/cisplatin combination chemotherapy as first-line treatment in patients with stage IIIB/IV non-small cell lung cancer with epidermal growth factor receptor (EGFR) mutations in their tumours. Patients were randomized to receive either Tarceva 150 mg orally daily or 3-week cycles of gemcitabine 1250 mg/m\^2 intravenously (iv) on Days 1 and 8 plus cisplatin 75 mg/m\^2 iv on Day 1.


Options:
A: Arm Label: Erlotinib; Type: EXPERIMENTAL; Interventions: Drug: Erlotinib | Arm Label: Chemotherapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: Chemotherapy | Intervention Type: DRUG; Name: Erlotinib; Assigned to Arm(s): Erlotinib | Intervention Type: DRUG; Name: Chemotherapy; Assigned to Arm(s): Chemotherapy
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Gefitinib | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Carboplatin, Drug: Paclitaxel | Intervention Type: DRUG; Name: Gefitinib; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): 2
C: Arm Label: erlotinib; Type: EXPERIMENTAL; Interventions: Drug: erlotinib | Arm Label: gemcitabine/carboplatin; Type: ACTIVE_COMPARATOR; Interventions: Drug: gemcitabine/carboplatin | Intervention Type: DRUG; Name: erlotinib; Assigned to Arm(s): erlotinib | Intervention Type: DRUG; Name: gemcitabine/carboplatin; Assigned to Arm(s): gemcitabine/carboplatin
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Platinum chemotherapy (cisplatin or carboplatin), Drug: erlotinib [Tarceva], Drug: gemcitabine | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Platinum chemotherapy (cisplatin or carboplatin), Drug: gemcitabine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Platinum chemotherapy (cisplatin or carboplatin); Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: erlotinib [Tarceva]; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: gemcitabine; Assigned to Arm(s): 1, 2

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-blind, Placebo-Controlled, Comparative Multicenter Phase 3 Study to Evaluate the Safety and Efficacy of BA058 (Abaloparatide) for Injection for Prevention of Fracture in Ambulatory Postmenopausal Women With Severe Osteoporosis and at Risk of Fracture
Brief Summary: The purpose of this study is to determine whether BA058 (abaloparatide), a parathyroid hormone-related peptide, is effective in preventing fractures in postmenopausal women with severe osteoporosis who are at risk of fractures.


Options:
A: Arm Label: Control, low turnover; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Treatment, low turnover; Type: EXPERIMENTAL; Interventions: Drug: Teriparatide, Drug: Cinacalcet | Arm Label: Control, high turnover; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Treatment, high turnover; Type: EXPERIMENTAL; Interventions: Drug: Alendronate | Intervention Type: DRUG; Name: Alendronate; Assigned to Arm(s): Treatment, high turnover | Intervention Type: DRUG; Name: Teriparatide; Assigned to Arm(s): Treatment, low turnover | Intervention Type: DRUG; Name: Cinacalcet; Assigned to Arm(s): Treatment, low turnover
B: Arm Label: Denosumab; Type: EXPERIMENTAL; Interventions: Drug: Denosumab | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: NaCl (placebo) | Intervention Type: DRUG; Name: Denosumab; Assigned to Arm(s): Denosumab | Intervention Type: DRUG; Name: NaCl (placebo); Assigned to Arm(s): Placebo
C: Arm Label: Romosozumab; Type: EXPERIMENTAL; Interventions: Drug: Romosozumab, Drug: Denosumab | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Denosumab | Intervention Type: DRUG; Name: Romosozumab; Assigned to Arm(s): Romosozumab | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Denosumab; Assigned to Arm(s): Placebo, Romosozumab
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: BA058 80 mcg (abaloparatide); Type: EXPERIMENTAL; Interventions: Drug: BA058 80 mcg | Arm Label: teriparatide; Type: ACTIVE_COMPARATOR; Interventions: Drug: teriparatide | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: BA058 80 mcg; Assigned to Arm(s): BA058 80 mcg (abaloparatide) | Intervention Type: DRUG; Name: teriparatide; Assigned to Arm(s): teriparatide

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Staying on Track: Increasing Completion of the HPV Vaccine Series With the Use of an Innovative Patient and Provider Information and Tracking Tool
Brief Summary: Planned Parenthood Federation of America's (PPFA) Medical Affairs Division will conduct a prospective, cluster randomized trial to determine which factors influence the acquisition of the second and third human papillomavirus (HPV) vaccine doses among young women ages 19 to 26. This descriptive and interventional study will provide data to assess impact of a computerized tool upon HPV vaccine series completion. The interventional aspect of this study includes determination of patient assistance and provider support programs applicable to each woman's situation as well as the implementation of a computer software system for customized patient reminders.


Options:
A: Arm Label: control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Parent Only Group; Type: EXPERIMENTAL; Interventions: Other: Parent Only Phone Call | Arm Label: Parent and Adolescent Group; Type: EXPERIMENTAL; Interventions: Other: Parent and Adolescent Phone Call | Intervention Type: OTHER; Name: Parent Only Phone Call; Assigned to Arm(s): Parent Only Group | Intervention Type: OTHER; Name: Parent and Adolescent Phone Call; Assigned to Arm(s): Parent and Adolescent Group
B: Arm Label: SMS Vaccine; Type: N/A; Interventions: Behavioral: SMS message reminding mothers to come for their scheduled vaccines | Arm Label: Usual care; Type: N/A; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: SMS message reminding mothers to come for their scheduled vaccines; Assigned to Arm(s): SMS Vaccine
C: Arm Label: Control, standard care for HPV vaccine; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Intervention, computer reminder system; Type: EXPERIMENTAL; Interventions: Behavioral: Computer reminder system | Intervention Type: BEHAVIORAL; Name: Computer reminder system; Assigned to Arm(s): Intervention, computer reminder system
D: Arm Label: Population-based Reminder/Recall; Type: EXPERIMENTAL; Interventions: Behavioral: Recall conducted centrally by local health department | Arm Label: Practice-based Reminder/Recall; Type: EXPERIMENTAL; Interventions: Behavioral: Recall conducted by private practices | Intervention Type: BEHAVIORAL; Name: Recall conducted by private practices; Assigned to Arm(s): Practice-based Reminder/Recall | Intervention Type: BEHAVIORAL; Name: Recall conducted centrally by local health department; Assigned to Arm(s): Population-based Reminder/Recall

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Staying on Track: Increasing Completion of the HPV Vaccine Series With the Use of an Innovative Patient and Provider Information and Tracking Tool
Brief Summary: Planned Parenthood Federation of America's (PPFA) Medical Affairs Division will conduct a prospective, cluster randomized trial to determine which factors influence the acquisition of the second and third human papillomavirus (HPV) vaccine doses among young women ages 19 to 26. This descriptive and interventional study will provide data to assess impact of a computerized tool upon HPV vaccine series completion. The interventional aspect of this study includes determination of patient assistance and provider support programs applicable to each woman's situation as well as the implementation of a computer software system for customized patient reminders.


Options:
A: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Intervention | Arm Label: Enhanced Standard of Care; Type: EXPERIMENTAL; Interventions: Behavioral: Enhanced Standard of Care | Arm Label: Traditional Standard of Care; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Traditional Standard of Care | Intervention Type: BEHAVIORAL; Name: Intervention; Assigned to Arm(s): Intervention | Intervention Type: BEHAVIORAL; Name: Enhanced Standard of Care; Assigned to Arm(s): Enhanced Standard of Care | Intervention Type: BEHAVIORAL; Name: Traditional Standard of Care; Assigned to Arm(s): Traditional Standard of Care
B: Arm Label: Connected to Care; Type: EXPERIMENTAL; Interventions: Behavioral: Connected to Care | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Connected to Care; Assigned to Arm(s): Connected to Care
C: Arm Label: Control, standard care for HPV vaccine; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Intervention, computer reminder system; Type: EXPERIMENTAL; Interventions: Behavioral: Computer reminder system | Intervention Type: BEHAVIORAL; Name: Computer reminder system; Assigned to Arm(s): Intervention, computer reminder system
D: Arm Label: Standard of Care (SoC); Type: NO_INTERVENTION; Interventions: N/A | Arm Label: SoC + iTab; Type: ACTIVE_COMPARATOR; Interventions: Device: SoC + iTab | Intervention Type: DEVICE; Name: SoC + iTab; Assigned to Arm(s): SoC + iTab

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Enhancing Participation of Chronic Stroke Patients in Primary Care by Modified Constraint Induced Movement Therapy (HOMECIMT)
Brief Summary: The aim of this study is to evaluate the efficacy of a modified approach of constraint induced movement therapy ("CIMT at home") for chronic stroke patients, compared to conventional physiotherapy and occupational therapy ("therapy as usual) with regard to the ability to participate in everyday activities.


Options:
A: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Tele-Rehabilitation; Type: EXPERIMENTAL; Interventions: Other: Tele-rehabilitation | Intervention Type: OTHER; Name: Tele-rehabilitation; Assigned to Arm(s): Tele-Rehabilitation
B: Arm Label: Self-Directed Program; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Self-directed program | Arm Label: Stroke Support Person; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Timing it Right Stroke Family Support Person Intervention | Arm Label: Standard Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Timing it Right Stroke Family Support Person Intervention; Assigned to Arm(s): Stroke Support Person | Intervention Type: BEHAVIORAL; Name: Self-directed program; Assigned to Arm(s): Self-Directed Program
C: Arm Label: mod. Constraint-Induced Movement Therapy; Type: EXPERIMENTAL; Interventions: Behavioral: mod. Constraint-Induced Movement Therapy | Arm Label: Therapy as usual; Type: OTHER; Interventions: Other: Therapy as usual | Intervention Type: BEHAVIORAL; Name: mod. Constraint-Induced Movement Therapy; Assigned to Arm(s): mod. Constraint-Induced Movement Therapy | Intervention Type: OTHER; Name: Therapy as usual; Assigned to Arm(s): Therapy as usual
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Other: Family Mediated Exercise Therapy | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Family Mediated Exercise Therapy; Assigned to Arm(s): 1

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Yoga vs. Physical Therapy vs. Education for Chronic Low Back Pain in Minority Populations (Back to Health)
Brief Summary: A randomized controlled trial for chronic low back pain in predominantly minority populations with three treatment arms: yoga, physical therapy, and education. Four cohorts of participants will be randomized in a 2:2:1 ratio (yoga:physical therapy:education). Primary outcomes are pain intensity and measure of disability; secondary outcomes are pain medication use, treatment adherence, and health-related quality of life.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: General health talk, Behavioral: Handout of The Back Book, Behavioral: Back exercise | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Handout of The Back Book, Behavioral: Back exercise | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Back exercise | Intervention Type: BEHAVIORAL; Name: General health talk; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Handout of The Back Book; Assigned to Arm(s): 1, 2 | Intervention Type: BEHAVIORAL; Name: Back exercise; Assigned to Arm(s): 1, 2, 3
B: Intervention Type: BEHAVIORAL; Name: Fear-reducing Information; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Symptom-based exercise; Assigned to Arm(s): N/A
C: Arm Label: Yoga; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Weekly yoga classes | Arm Label: Physical Therapy; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Individual physical therapy treatment | Arm Label: Education; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Education | Intervention Type: BEHAVIORAL; Name: Weekly yoga classes; Assigned to Arm(s): Yoga | Intervention Type: BEHAVIORAL; Name: Individual physical therapy treatment; Assigned to Arm(s): Physical Therapy | Intervention Type: BEHAVIORAL; Name: Education; Assigned to Arm(s): Education
D: Arm Label: Virtual reality group; Type: EXPERIMENTAL; Interventions: Other: Virtual reality exercise group | Arm Label: Control group; Type: ACTIVE_COMPARATOR; Interventions: Other: Conventional exercise group (control group) | Intervention Type: OTHER; Name: Virtual reality exercise group; Assigned to Arm(s): Virtual reality group | Intervention Type: OTHER; Name: Conventional exercise group (control group); Assigned to Arm(s): Control group

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Yoga vs. Physical Therapy vs. Education for Chronic Low Back Pain in Minority Populations (Back to Health)
Brief Summary: A randomized controlled trial for chronic low back pain in predominantly minority populations with three treatment arms: yoga, physical therapy, and education. Four cohorts of participants will be randomized in a 2:2:1 ratio (yoga:physical therapy:education). Primary outcomes are pain intensity and measure of disability; secondary outcomes are pain medication use, treatment adherence, and health-related quality of life.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Yoga | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Exercise | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Self-care book recommendations | Intervention Type: BEHAVIORAL; Name: Yoga; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Exercise; Assigned to Arm(s): 2 | Intervention Type: BEHAVIORAL; Name: Self-care book recommendations; Assigned to Arm(s): 3
B: Arm Label: Yoga; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Weekly yoga classes | Arm Label: Physical Therapy; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Individual physical therapy treatment | Arm Label: Education; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Education | Intervention Type: BEHAVIORAL; Name: Weekly yoga classes; Assigned to Arm(s): Yoga | Intervention Type: BEHAVIORAL; Name: Individual physical therapy treatment; Assigned to Arm(s): Physical Therapy | Intervention Type: BEHAVIORAL; Name: Education; Assigned to Arm(s): Education
C: Intervention Type: BEHAVIORAL; Name: Yoga; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Exercise; Assigned to Arm(s): N/A
D: Arm Label: Yoga Class Twice Per Week; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Yoga class twice per week | Arm Label: Yoga Class Once per Week; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Yoga class once per week | Intervention Type: BEHAVIORAL; Name: Yoga class once per week; Assigned to Arm(s): Yoga Class Once per Week | Intervention Type: BEHAVIORAL; Name: Yoga class twice per week; Assigned to Arm(s): Yoga Class Twice Per Week

Answer: B